Caris Life Sciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Caris Life Sciences, Inc. (CAI) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Operating Activities
Net Income-281.89-341.42-320.83
Depreciation & Amortization48.9149.0048.25
Stock Based Compensation18.6415.2422.90
Change in Working Capital-29.07-7.13-22.26
Change in Accounts Receivable-33.82-15.08-11.91
Change in Inventory5.46-4.44-11.10
Change in Accounts Payable-0.237.178.91
Change in Other Working Capital-0.485.226.98
Other Operating Activities-8.852.826.98
Net Cash from Operating Activities-245.20-276.10-285.71
Investing Activities
Capital Expenditures-8.44-22.32-42.26
Purchases of Investments61.38237.09-378.38
Sales/Maturities of Investments61.38300.49137.65
Net Cash from Investing Activities52.93214.77-282.99
Financing Activities
Debt Repayment-0.16-180.74-0.96
Common Stock Issued1.531.8711.41
Other Financing Activities-1.06-2.300.00
Net Cash from Financing Activities200.2910.1310.45
Summary
Effect of Forex Changes on Cash0.000.060.00
Net Change in Cash8.02-51.13-558.25
Cash at Beginning of Period60.01111.14669.38
Cash at End of Period68.0360.01111.14
Free Cash Flow-253.64-298.42-327.96
Supplemental Disclosures
Interest Paid49.0215.7824.24